TY - JOUR
T1 - Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia – a matched pair analysis by the Acute Leukaemia Working Party of EBMT
AU - on behalf of the EBMT Acute Leukaemia Working Party
AU - Schmid, Christoph
AU - Labopin, Myriam
AU - Schaap, Nicolaas
AU - Veelken, Hendrik
AU - Schleuning, Michael
AU - Stadler, Michael
AU - Finke, Juergen
AU - Hurst, Erin
AU - Baron, Frederic
AU - Ringden, Olle
AU - Bug, Gesine
AU - Blaise, Didier
AU - Tischer, Johanna
AU - Bloor, Adrian
AU - Esteve, Jordi
AU - Giebel, Sebastian
AU - Savani, Bipin
AU - Gorin, Norbert Claude
AU - Ciceri, Fabio
AU - Mohty, Mohamad
AU - Nagler, Arnon
PY - 2019/3
Y1 - 2019/3
N2 - Strategies for relapse prevention after allogeneic transplantation in acute leukaemia are warranted. A registry-based matched-pair analysis evaluated the efficacy of prophylactic donor lymphocyte infusion (proDLI). Adults receiving proDLI in complete remission (CR) and controls were pair-matched for age, diagnosis, cytogenetics, stage, donor, gender, conditioning and T-cell depletion. Eighty-nine pairs were identified (median follow-up: 6.9 years). Within the entire cohort, no difference was observed. However, among patients with high-risk acute myeloid leukaemia (AML) (unfavourable cytogenetics and/or transplanted beyond first CR), proDLI recipients had improved overall survival (69.8% vs. 40.2% in controls, P = 0.027). ProDLI has moderate efficacy, but can contribute to improved outcome in high-risk AML.
AB - Strategies for relapse prevention after allogeneic transplantation in acute leukaemia are warranted. A registry-based matched-pair analysis evaluated the efficacy of prophylactic donor lymphocyte infusion (proDLI). Adults receiving proDLI in complete remission (CR) and controls were pair-matched for age, diagnosis, cytogenetics, stage, donor, gender, conditioning and T-cell depletion. Eighty-nine pairs were identified (median follow-up: 6.9 years). Within the entire cohort, no difference was observed. However, among patients with high-risk acute myeloid leukaemia (AML) (unfavourable cytogenetics and/or transplanted beyond first CR), proDLI recipients had improved overall survival (69.8% vs. 40.2% in controls, P = 0.027). ProDLI has moderate efficacy, but can contribute to improved outcome in high-risk AML.
KW - acute leukaemia
KW - allogeneic stem cell transplantation
KW - DLI
KW - relapse prevention
UR - http://www.scopus.com/inward/record.url?scp=85057026666&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057026666&partnerID=8YFLogxK
U2 - 10.1111/bjh.15691
DO - 10.1111/bjh.15691
M3 - Article
C2 - 30467839
AN - SCOPUS:85057026666
VL - 184
SP - 782
EP - 787
JO - British Journal of Haematology
JF - British Journal of Haematology
SN - 0007-1048
IS - 5
ER -